CatSci buys Reach Separations

Drug development services supplier CatSci has acquired its UK compatriot Reach Separations. No financial details were disclosed but the company said that this deal was supported by Keensight Capital, a private equity manager dedicated to pan-European growth buyout investments. The whole of the Reach Separations will transfer and the companies will be fully integrated.

Reach Separations has laboratories in the UK and France, and specialises in HPLC and large-scale supercritical fluid chromatography for the analysis and purification of chiral and achiral drug candidates, notably small molecules and oligonucleotides, as well as Targeting Chimeras and glues. CatSci said that it will now be able to offer “access to holistic chromatographic services that will aid customers from discovery through to manufacture, catering to full asset development or stand-alone projects”.